Studies Analyzing Association of Blood Cryptococcal Antigen Titer and Subsequent Cryptococcal Meningitis and/or Death
Country . | Year . | Study design . | Association between blood CrAg titer and CM and/or mortality . | Notes . | Ref . |
---|---|---|---|---|---|
Association between blood CrAg titer and subsequent CM and/or mortality . | |||||
South Africa | 2009 | Retrospective analysis of CrAg titers (using Latex Agglutination, LA) on pre-ART blood samples from 46 patients. | Higher baseline titer associated with increased risk of mortality (p=0.02), subsequent cryptococcal meningitis (p=0.03) and relapse (all >512) within 1 y. | No baseline LP performed. Symptoms and fluconazole use unknown. | [1] |
Tanzania | 2011 | CrAg screening of all HIV positive hospital admissions. Serum CrAg titers (LFA) on 17/333 CrAg-positive patients. | Higher titer associated with mortality (p=0.004). | All symptomatic, 15/17 had cryptococcal meningitis. | [17] |
Tanzania | 2015 | Retrospective analysis of blood CrAg titers (using LFA) on pre-ART blood samples from 21 asymptomatic patients. | Titer of >160 associated with subsequent cryptococcal meningitis (adjusted OR, 4.83; 95% CI, 1.24–8.41; P = .008) within 1 y. | 3 patients with titers ≤160 died of unknown causes. | [11] |
Uganda | 2016 | Cluster randomized trial of CrAg screen and treat strategy. CrAg titers (LFA) on 151 asymptomatic patients. | Titer of ≥160 associated with subsequent cryptococcal meningitis (HR 9.2, 95% CI 2.14-39.58, p<0.01) (unpublished data) | Increased risk of death or subsequent cryptococcal meningitis if titer ≥160 and CD4 ≤50. | [20] |
Country . | Year . | Study design . | Association between blood CrAg titer and CM and/or mortality . | Notes . | Ref . |
---|---|---|---|---|---|
Association between blood CrAg titer and subsequent CM and/or mortality . | |||||
South Africa | 2009 | Retrospective analysis of CrAg titers (using Latex Agglutination, LA) on pre-ART blood samples from 46 patients. | Higher baseline titer associated with increased risk of mortality (p=0.02), subsequent cryptococcal meningitis (p=0.03) and relapse (all >512) within 1 y. | No baseline LP performed. Symptoms and fluconazole use unknown. | [1] |
Tanzania | 2011 | CrAg screening of all HIV positive hospital admissions. Serum CrAg titers (LFA) on 17/333 CrAg-positive patients. | Higher titer associated with mortality (p=0.004). | All symptomatic, 15/17 had cryptococcal meningitis. | [17] |
Tanzania | 2015 | Retrospective analysis of blood CrAg titers (using LFA) on pre-ART blood samples from 21 asymptomatic patients. | Titer of >160 associated with subsequent cryptococcal meningitis (adjusted OR, 4.83; 95% CI, 1.24–8.41; P = .008) within 1 y. | 3 patients with titers ≤160 died of unknown causes. | [11] |
Uganda | 2016 | Cluster randomized trial of CrAg screen and treat strategy. CrAg titers (LFA) on 151 asymptomatic patients. | Titer of ≥160 associated with subsequent cryptococcal meningitis (HR 9.2, 95% CI 2.14-39.58, p<0.01) (unpublished data) | Increased risk of death or subsequent cryptococcal meningitis if titer ≥160 and CD4 ≤50. | [20] |
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; CM, cryptococcal meningitis; CrAg, cryptococcal antigen; HIV, human immunodeficiency virus; HR, hazard ratio; LA, latex agglutination; LFA, lateral flow assay; LP, lumbar puncture; OR, odds ratio.
Studies Analyzing Association of Blood Cryptococcal Antigen Titer and Subsequent Cryptococcal Meningitis and/or Death
Country . | Year . | Study design . | Association between blood CrAg titer and CM and/or mortality . | Notes . | Ref . |
---|---|---|---|---|---|
Association between blood CrAg titer and subsequent CM and/or mortality . | |||||
South Africa | 2009 | Retrospective analysis of CrAg titers (using Latex Agglutination, LA) on pre-ART blood samples from 46 patients. | Higher baseline titer associated with increased risk of mortality (p=0.02), subsequent cryptococcal meningitis (p=0.03) and relapse (all >512) within 1 y. | No baseline LP performed. Symptoms and fluconazole use unknown. | [1] |
Tanzania | 2011 | CrAg screening of all HIV positive hospital admissions. Serum CrAg titers (LFA) on 17/333 CrAg-positive patients. | Higher titer associated with mortality (p=0.004). | All symptomatic, 15/17 had cryptococcal meningitis. | [17] |
Tanzania | 2015 | Retrospective analysis of blood CrAg titers (using LFA) on pre-ART blood samples from 21 asymptomatic patients. | Titer of >160 associated with subsequent cryptococcal meningitis (adjusted OR, 4.83; 95% CI, 1.24–8.41; P = .008) within 1 y. | 3 patients with titers ≤160 died of unknown causes. | [11] |
Uganda | 2016 | Cluster randomized trial of CrAg screen and treat strategy. CrAg titers (LFA) on 151 asymptomatic patients. | Titer of ≥160 associated with subsequent cryptococcal meningitis (HR 9.2, 95% CI 2.14-39.58, p<0.01) (unpublished data) | Increased risk of death or subsequent cryptococcal meningitis if titer ≥160 and CD4 ≤50. | [20] |
Country . | Year . | Study design . | Association between blood CrAg titer and CM and/or mortality . | Notes . | Ref . |
---|---|---|---|---|---|
Association between blood CrAg titer and subsequent CM and/or mortality . | |||||
South Africa | 2009 | Retrospective analysis of CrAg titers (using Latex Agglutination, LA) on pre-ART blood samples from 46 patients. | Higher baseline titer associated with increased risk of mortality (p=0.02), subsequent cryptococcal meningitis (p=0.03) and relapse (all >512) within 1 y. | No baseline LP performed. Symptoms and fluconazole use unknown. | [1] |
Tanzania | 2011 | CrAg screening of all HIV positive hospital admissions. Serum CrAg titers (LFA) on 17/333 CrAg-positive patients. | Higher titer associated with mortality (p=0.004). | All symptomatic, 15/17 had cryptococcal meningitis. | [17] |
Tanzania | 2015 | Retrospective analysis of blood CrAg titers (using LFA) on pre-ART blood samples from 21 asymptomatic patients. | Titer of >160 associated with subsequent cryptococcal meningitis (adjusted OR, 4.83; 95% CI, 1.24–8.41; P = .008) within 1 y. | 3 patients with titers ≤160 died of unknown causes. | [11] |
Uganda | 2016 | Cluster randomized trial of CrAg screen and treat strategy. CrAg titers (LFA) on 151 asymptomatic patients. | Titer of ≥160 associated with subsequent cryptococcal meningitis (HR 9.2, 95% CI 2.14-39.58, p<0.01) (unpublished data) | Increased risk of death or subsequent cryptococcal meningitis if titer ≥160 and CD4 ≤50. | [20] |
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; CM, cryptococcal meningitis; CrAg, cryptococcal antigen; HIV, human immunodeficiency virus; HR, hazard ratio; LA, latex agglutination; LFA, lateral flow assay; LP, lumbar puncture; OR, odds ratio.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.